RevMed Q3 2026 pill revenue exceeds $50M
Resolves: RevMed's Q3 2026 earnings report shows pill revenue > $50M.
user-generated· earnings
RevMed Q3 2026 pill revenue exceeds $50M
Market overview
RevMed reports Q3 2026 revenue from the pancreatic cancer pill above $50 million.
earnings prediction market
- Implied probability (Yes)
- 40%
- Closes
- 2026-11-15
About this prediction
Resolution criteria
RevMed's Q3 2026 earnings report shows pill revenue > $50M.
Source: user-generated
More earnings markets
- Will cash burn exceed $5M in Q4? — 65% Yes
- Will Venyra beat Q4 2026 revenue consensus of $230M? — 85% Yes
- Will Nuburu secure emergency financing by Q3 end? — 35% Yes
- Will Everpure, Inc. report a non-GAAP EPS beat for the quarter ended June 30, 2026? — 50% Yes
- Will KR miss Q4 operating margin guidance? — 65% Yes
- Will George Risk report Q4 2026 revenue above $13M? — 85% Yes
- Will DCI beat Q4 EPS consensus of $0.88? — 65% Yes
- Will inventory days decrease below 70 by year-end? — 40% Yes
No one's made a Conviction call on this yet. Be the first to call it →
Loading…